Published in Am J Pathol on April 01, 2003
p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Mammalian Krüppel-like factors in health and diseases. Physiol Rev (2010) 4.09
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6. Blood (2005) 1.39
KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J Clin Invest (2008) 1.36
KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem (2008) 1.23
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol (2009) 1.22
Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology (2008) 1.21
Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med (2006) 1.12
Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol (2008) 1.09
Expression and Function of Kruppel Like-Factors (KLF) in Carcinogenesis. Curr Genomics (2009) 1.01
Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One (2010) 0.99
Molecular pathways in prostate cancer. Nephrourol Mon (2013) 0.92
TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction. Biochem J (2009) 0.92
Zinc and cancer: implications for LIV-1 in breast cancer. Nutrients (2012) 0.91
Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes. Br J Cancer (2003) 0.91
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets (2009) 0.91
Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. J Biol Chem (2011) 0.86
Krüppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol (2003) 0.86
Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer (2008) 0.85
Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma. World J Gastroenterol (2007) 0.85
Aberrant expression of krUppel-like factor 6 protein in colorectal cancers. World J Gastroenterol (2006) 0.84
KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation. Am J Pathol (2012) 0.83
Nuclear expression of KLF6 tumor suppressor factor is highly associated with overexpression of ERBB2 oncoprotein in ductal breast carcinomas. PLoS One (2010) 0.83
Identification and characterization of putative tumor suppressor NGB, a GTP-binding protein that interacts with the neurofibromatosis 2 protein. Mol Cell Biol (2007) 0.82
A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. Gastric Cancer (2011) 0.81
Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma. Oncotarget (2016) 0.78
Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. Mt Sinai J Med (2009) 0.77
Krüppel-like factors in mammalian stem cells and development. Development (2017) 0.75
KLF6SV1 siRNA inhibits proliferation of human lens epithelial cells. Mol Vis (2012) 0.75
Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer. Am J Pathol (2012) 0.75
Establishment of transgenic mice carrying gene encoding human zinc finger protein 191. World J Gastroenterol (2004) 0.75
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res (1999) 3.68
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (2001) 3.22
Decreased expression of the gut-enriched Krüppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. FEBS Lett (2000) 1.70
A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene (2002) 1.55
Tissue, cell type, and breast cancer stage-specific expression of a TGF-beta inducible early transcription factor gene. J Cell Biochem (1998) 1.23
Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res (1996) 1.19
Genetics and etiology of human cancer. Adv Hum Genet (1977) 1.19
Allelotyping of human prostatic adenocarcinoma. Genomics (1991) 1.16
Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer (2001) 1.11
Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer (1999) 1.10
Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res (1996) 1.02
Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol (1994) 1.02
Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res (2000) 1.02
Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer (1996) 0.99
Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet (2000) 0.97
An 800-kb region of deletion at 13q14 in human prostate and other carcinomas. Genomics (2001) 0.93
Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res (1996) 0.90
A novel human cancer culture model for the study of prostate cancer. Oncogene (2001) 0.86
Functional evidence for the presence of tumor suppressor gene on chromosome 10p15 in human prostate cancers. Oncogene (2001) 0.86
High frequency of clonal chromosome abnormalities in prostatic neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy. Genes Chromosomes Cancer (2000) 0.82
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods (2013) 3.63
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol (2003) 3.59
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol (2006) 2.29
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol (2006) 2.29
LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 2.28
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res (2008) 2.16
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res (2003) 2.14
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) (2003) 2.05
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res (2002) 2.01
Profiling the evolution of human metastatic bladder cancer. Cancer Res (2004) 2.00
Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology (2003) 1.94
Tissues from population-based cancer registries: a novel approach to increasing research potential. Hum Pathol (2005) 1.92
Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91
Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer (2006) 1.88
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet (2002) 1.86
Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer (2002) 1.83
Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene (2004) 1.82
Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res (2002) 1.81
Implication of snoRNA U50 in human breast cancer. J Genet Genomics (2009) 1.80
CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated. Proc Natl Acad Sci U S A (2012) 1.79
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate (2002) 1.78
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.77
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (2007) 1.75
Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer (2005) 1.73
CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol (2005) 1.72
FOXL2 and BPES: mutational hotspots, phenotypic variability, and revision of the genotype-phenotype correlation. Am J Hum Genet (2003) 1.70
DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci U S A (2009) 1.69
Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res (2009) 1.69
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene (2005) 1.64
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One (2012) 1.63
SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet (2008) 1.62
Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem (2005) 1.56
A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene (2002) 1.55
Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res (2005) 1.55
Co-infections with Plasmodium knowlesi and other malaria parasites, Myanmar. Emerg Infect Dis (2010) 1.53
GJA1 mutations, variants, and connexin 43 dysfunction as it relates to the oculodentodigital dysplasia phenotype. Hum Mutat (2009) 1.52
Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol (2003) 1.50
Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol (2011) 1.48
KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate (2003) 1.47
KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer (2006) 1.44
Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res (2005) 1.43
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis (2007) 1.41
The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res (2006) 1.41
Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res (2005) 1.41
The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem (2008) 1.39
Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat (2008) 1.34
Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol (2011) 1.33
Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res (2002) 1.33
Epigenetic Silencing of miR-203 Upregulates SNAI2 and Contributes to the Invasiveness of Malignant Breast Cancer Cells. Genes Cancer (2011) 1.32
Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res (2008) 1.32
Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res (2008) 1.30
The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer (2006) 1.30
KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem (2006) 1.30
Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate (2003) 1.30
EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A. Proc Natl Acad Sci U S A (2008) 1.28
The lacrimal gland transcriptome is an unusually rich source of rare and poorly characterized gene transcripts. Invest Ophthalmol Vis Sci (2005) 1.27
The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer (2007) 1.26
The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem (2007) 1.26
Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol (2009) 1.25
Osteoprotegerin in prostate cancer bone metastasis. Cancer Res (2005) 1.24
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer (2006) 1.23
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One (2013) 1.23
Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate (2003) 1.22
Oncogenic function of microtubule end-binding protein 1 in breast cancer. J Pathol (2010) 1.22
Molecular analysis of chloroquine resistance in Plasmodium falciparum in Yunnan Province, China. Trop Med Int Health (2007) 1.21
Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J Biol Chem (2008) 1.21
Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate (2010) 1.21
Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation. Cancer Discov (2012) 1.20
Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Genes Chromosomes Cancer (2008) 1.20
Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer (2005) 1.20